Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?
作者信息
Pereira Naveen L, Desai Viral K, Jaffe Allan S
机构信息
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
出版信息
Eur J Heart Fail. 2019 May;21(5):609-612. doi: 10.1002/ejhf.1451. Epub 2019 Mar 4.
Abstract
摘要
相似文献
1
Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?沙库巴曲缬沙坦对射血分数降低的心力衰竭的有益作用：并非因为脑钠肽？
Eur J Heart Fail. 2019 May;21(5):609-612. doi: 10.1002/ejhf.1451. Epub 2019 Mar 4.
2
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
3
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.沙库巴曲缬沙坦对慢性心力衰竭脑啡肽酶靶点及利钠肽代谢的影响：一项机制性临床研究。
Eur J Heart Fail. 2019 May;21(5):598-605. doi: 10.1002/ejhf.1342. Epub 2018 Dec 6.
4
Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found.
J Am Coll Cardiol. 2024 Mar 5;83(9):915-917. doi: 10.1016/j.jacc.2024.01.009.
5
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.尿 cGMP（环鸟苷酸单磷酸）/BNP（B 型利钠肽）比值、沙库巴曲缬沙坦与射血分数降低的心力衰竭结局：PARADIGM-HF 试验分析。
Circ Heart Fail. 2023 Mar;16(3):e010111. doi: 10.1161/CIRCHEARTFAILURE.122.010111. Epub 2023 Jan 25.
6
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
7
Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.血管紧张素受体脑啡肽酶抑制剂对射血分数降低的心力衰竭患者肺动脉僵硬度的影响。
Int J Cardiovasc Imaging. 2021 Jan;37(1):165-173. doi: 10.1007/s10554-020-01973-8. Epub 2020 Aug 19.
8
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.沙库巴曲缬沙坦治疗期间的 B 型利钠肽：PARADIGM-HF 试验。
J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018. Epub 2019 Mar 4.
9
Sacubitril/Valsartan (LCZ696) in Heart Failure.沙库巴曲缬沙坦（LCZ696）用于心力衰竭治疗
Handb Exp Pharmacol. 2017;243:133-165. doi: 10.1007/164_2016_77.
10
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.奈普利酶抑制对各种利钠肽检测的影响。
J Am Coll Cardiol. 2019 Mar 26;73(11):1273-1284. doi: 10.1016/j.jacc.2018.12.063.
引用本文的文献
1
B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?再探B型利钠肽（BNP）——在血管紧张素受体/中性肽链内切酶抑制剂时代，BNP仍是心力衰竭的生物标志物吗？
Biology (Basel). 2022 Jul 9;11(7):1034. doi: 10.3390/biology11071034.
本文引用的文献
1
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.急性失代偿性心力衰竭后血管紧张素-脑啡肽酶抑制剂的启动：PIONEER-HF 试验开放标签扩展的二次分析。
JAMA Cardiol. 2020 Feb 1;5(2):202-207. doi: 10.1001/jamacardio.2019.4665.
2
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.沙库巴曲缬沙坦对慢性心力衰竭脑啡肽酶靶点及利钠肽代谢的影响：一项机制性临床研究。
Eur J Heart Fail. 2019 May;21(5):598-605. doi: 10.1002/ejhf.1342. Epub 2018 Dec 6.
3
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).前瞻性研究生物标志物、症状改善和沙库巴曲缬沙坦治疗心力衰竭期间心室重构的原理和方法（PROVE-HF）。
Am Heart J. 2018 May;199:130-136. doi: 10.1016/j.ahj.2017.12.021. Epub 2018 Feb 13.
4
Natriuretic Peptides and Analytical Barriers.利钠肽与分析障碍
Clin Chem. 2017 Jan;63(1):50-58. doi: 10.1373/clinchem.2016.254714. Epub 2016 Oct 10.
5
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.心力衰竭患者 N 端脑利钠肽前体水平变化的预后意义。
J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436. doi: 10.1016/j.jacc.2016.09.931.
6
A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.在背景下的检验：脑啡肽酶：功能、抑制和生物标志物。
J Am Coll Cardiol. 2016 Aug 9;68(6):639-653. doi: 10.1016/j.jacc.2016.04.060.
7
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.沙库巴曲缬沙坦（LCZ696）在射血分数降低的心力衰竭患者中的药效学和药代动力学特征
Cardiovasc Ther. 2016 Aug;34(4):191-8. doi: 10.1111/1755-5922.12183.
8
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.B型利钠肽（BNP）和BNP前体（proBNP）对中性内肽酶切割的不同敏感性：N端部分至关重要。
Clin Chem. 2016 Apr;62(4):617-22. doi: 10.1373/clinchem.2016.254524. Epub 2016 Feb 10.
9
Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.血浆 B 型利钠肽浓度升高可直接抑制心力衰竭患者循环中性肽酶活性。
JACC Heart Fail. 2015 Aug;3(8):629-36. doi: 10.1016/j.jchf.2015.03.011.
10
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.血管紧张素受体脑啡肽酶抑制剂与依那普利比较，对心力衰竭存活患者临床进展风险的影响。
Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.
Zotero 插件